Emergency pharmaceutical - qualsody (TOFERSEN)
Ended Awarded
- Contract number
- 36C26124N0873
- Awardee
-
Biogen U.s. Corporation UEI E82LHNZSCUA3
- Awarding agency
-
Veterans Integrated Service Network 21
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $21,738
Award facts
- Contract value 100% obligated
- $21,738.30 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Cambridge, MA 02142, USA
Award details come from SAM.gov/FPDS.
About this award
This federal contract award to Biogen U.S. Corporation is for the delivery of the pharmaceutical product QALSODY (tofersen) to the U.S. Department of Veterans Affairs (VA). The $21,738.30 firm fixed price delivery order is placed against Biogen's Pharmaceuticals and Drugs GSA Schedule contract. The contract has no set-aside designation, indicating Biogen competed against other vendors to secure this award.
Biogen U.S. Corporation is a subsidiary of Biogen Idec Incorporated that focuses on developing therapies for neurological diseases. Through this contract, the company is supplying the VA with a specialized pharmaceutical product, likely used to treat neurological conditions in veterans. Biogen has been awarded multiple delivery orders by the VA's Veterans Integrated Service Networks (VISNs) 20 and 21, with the current award for delivery to a facility in Cambridge, Massachusetts.
In addition to this specific delivery order, Biogen U.S. Corporation holds two larger Indefinite Delivery Vehicles (IDVs) with the VA National Acquisition Center. One is a single-award indefinite delivery contract worth up to $11.39 million for the supply of ranibizumab vials and syringes, used to treat eye conditions. The other is a Blanket Purchase Agreement worth up to $430,578.10 for the drug Spinraza, used to treat spinal muscular atrophy. These IDVs allow the VA to efficiently procure essential pharmaceuticals for veterans nationwide.
Quick answers
Who was awarded contract 36C26124N0873?
36C26124N0873 was awarded to Biogen U.s. Corporation by Veterans Integrated Service Network 21 (Veterans Health Administration) on September 4, 2024.
How much is contract 36C26124N0873 worth?
The government has obligated $21,738 on 36C26124N0873.
Is contract 36C26124N0873 an order under another contract?
Yes. 36C26124N0873 is a delivery order under 36F79718D0566, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26124N0873 competed?
The extent of competition for 36C26124N0873 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award